Gene Expression and Molecular Pathways Associated With Rapid Antidepressant Response to Ketamine in Patients With Treatment Resistant Depression

      Ketamine is an NMDA receptor antagonist and glutamate modulator with rapid antidepressant effects in patients with treatment resistant depression (TRD). To gain insights into the etiopathology of TRD and ketamine’s mechanism of action, we examined gene expression profiles in patients compared to healthy controls (HC) and in patients before and after ketamine treatment.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect